SCHEMBL21303628

SCHEMBL21303628

c1nc2cc(NCc3ccc(N4CCOCC4)cc3)cnc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 4/20 0.57
▸ DYRK1A Q13627 4/20 0.57
▸ L3MBTL1 Q9Y468 4/20 0.52
▸ MAPT P10636 3/20 0.52
▸ ALOX12 P18054 3/20 0.52
▸ GAA P10253 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ PIK3CD O00329 1/20 0.46
▸ PIK3CA P42336 1/20 0.46
▸ PIK3CB P42338 1/20 0.46
▸ JAK2 O60674 2/20 0.44
▸ JAK1 P23458 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21303666 0.82 LTA4H (0.48) RAB9ANPC1
SCHEMBL21303627 0.77 RAB9A (0.47) MAPTRAB9AKDM4ENPC1ALDH1A1
SCHEMBL21303623 0.77 PRMT6 (0.50) CLK1DYRK1AL3MBTL1MAPTALOX12
SCHEMBL22448314 0.77 IP6K1 (0.56) HTTALDH1A1MAPK1LMNA
SCHEMBL21303602 0.76 GAA (0.46) CLK1DYRK1AL3MBTL1MAPTGAA
SCHEMBL21303610 0.75 QPCT (0.47) CLK1DYRK1AGAAALDH1A1MAPK1
SCHEMBL21303660 0.75 IP6K1 (0.51) CLK1DYRK1A
SCHEMBL21303664 0.74 MAPT (0.51) CLK1DYRK1AL3MBTL1MAPTGAA
SCHEMBL30855012 0.72 MAPT (0.89) CLK1DYRK1AL3MBTL1MAPTALOX12
SCHEMBL21303624 0.71 ABL1 (0.42) CLK1DYRK1AL3MBTL1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11958871-B2 Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-04-16 — — US disclosed
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2020-12-17 — — US disclosed
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2020-12-17 — — US disclosed
EP-3589632-B1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) 2020-09-23 — — EP disclosed
EP-3589632-B1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) 2020-09-23 — — EP disclosed
WO-2019162458-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2019-08-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES GMPS, GLS, QPCT CLK1 2815/4885DYRK1A 4411/4885L3MBTL1 3905/4885
US-11958871-B2 Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases GMPS, GLS, QPCT CLK1 2925/4885DYRK1A 4459/4885L3MBTL1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback